The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome.
OBJECTIVE
The purpose of this study is to summarize the role of anti-Müllerian hormone (AMH) in assisted reproductive technology (ART) treatment.


RESULTS
AMH is a good marker in the prediction of ovarian response to controlled ovarian hyperstimulation. In clinical practice, this means that AMH may be used for identifying poor or excessive responders. So far, studies show that AMH is not a good predictor for the occurrence of pregnancy after ART treatment. Therefore, routine screening for a poor ovarian reserve status using AMH is not to be advocated. Still, ovarian response prediction using AMH may open ways for patient-tailored stimulation protocols in order to reduce cancellations for excessive response, possibly improve pregnancy prospects and reduce costs.


CONCLUSIONS
AMH is able to predict extremes in ovarian response to controlled ovarian hyperstimulation but cannot predict pregnancy after ART treatment. Its future clinical role may be in the individualization of ART stimulation protocols.
Broer
Simone L
SL
Department of Reproductive Medicine, Division of Obstetrics, Neonatology and Gynecology, University Medical Center Utrecht, Utrecht, The Netherlands. S.L.Broer@umcutrecht.nl
Mol
BenWillem
B
Dólleman
Madeleine
M
Fauser
Bart C
BC
Broekmans
Frank J M
FJ
D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D006080:Ovarian Follicle / Q000166:cytology; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood / Q000175:diagnosis; D010062:Ovulation Induction; D011247:Pregnancy / Q000097:blood*; D011379:Prognosis; D027724:Reproductive Techniques, Assisted
D015415:Biomarkers; D054304:Anti-Mullerian Hormone